Japan’s Mitsui & Co. will collaborate with Singapore’s Oncoshot to use the firm’s AI platform for analyzing cancer-clinical data, aiming to expand oncology research across the hospital network of Malaysia’s IHH Healthcare.
In a statement on Friday, Mitsui said it has signed a service agreement with Oncoshot for the collaboration. Mitsui is IHH’s largest shareholder. The companies did not disclose financial terms of the agreement.
Oncoshot’s technology anonymizes and structures clinical data, such as electronic medical records and laboratory results, into research-ready datasets without moving the data out of the hospital. The approach can comply with privacy and data-governance rules that often restrict the sharing of patient data.
The partners aim to use real-world data, including information gathered in routine clinical care, to standardize oncology data, support international research, and shorten clinical-trial timelines. The cooperation can draw on more diverse patient populations.
Participating oncologists will include specialists in IHH’s network and others in the Asia-Pacific, Mitsui & Co. said. IHH, based in Kuala Lumpur, runs 89 hospitals across 10 countries under brands such as Gleneagles, Mount Elizabeth, Parkway, Pantai, Fortis, and Acibadem.
Mitsui said the tie-up fit its “Wellness Ecosystem Creation” strategy under its medium-term plan to 2029, aimed at expanding healthcare through IHH and supporting pharmaceutical development.
Yoichiro Endo, COO of Mitsui’s wellness business unit, said the company strives to raise care standards and make drug development more efficient through better use of clinical data and AI. Mitsui & Co. also aims to extend data collaboration to medical institutions in Japan and across the region.
Peter Chow, chief executive of IHH Healthcare Singapore, said the partnership would connect the group’s specialists with world-leading cancer institutions and strengthen oncology research.
Convergence in the blood: How AI and biotech are rewriting cancer detection across Asia